Positive News Sentiment NASDAQ:DYAI Dyadic International Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Dyadic International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.04 -0.01 (-0.33%) (As of 07/1/2022 03:59 PM ET) Add Compare Share Today's Range$3.03▼$3.0550-Day Range$1.85▼$3.2252-Week Range$1.74▼$6.89Volume1,773 shsAverage Volume26,933 shsMarket Capitalization$85.91 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Dyadic International MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside97.4% Upside$6.00 Price TargetShort InterestBearish2.08% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.87Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.23) to $0.03 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.99 out of 5 starsMedical Sector638th out of 1,428 stocksBiological Products, Except Diagnostic Industry104th out of 218 stocks 3.5 Analyst's Opinion Consensus RatingDyadic International has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Dyadic International has a forecasted upside of 97.4% from its current price of $3.04.Amount of Analyst CoverageDyadic International has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.08% of the float of Dyadic International has been sold short.Short Interest Ratio / Days to CoverDyadic International has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Dyadic International has recently increased by 5.19%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDyadic International does not currently pay a dividend.Dividend GrowthDyadic International does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DYAI. Previous Next 3.3 News and Social Media Coverage News SentimentDyadic International has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Dyadic International this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dyadic International insiders have not sold or bought any company stock.Percentage Held by Insiders26.50% of the stock of Dyadic International is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 26.12% of the stock of Dyadic International is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Dyadic International are expected to grow in the coming year, from ($0.23) to $0.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dyadic International is -6.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dyadic International is -6.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDyadic International has a P/B Ratio of 4.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DYAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dyadic International and its competitors with MarketBeat's FREE daily newsletter. Email Address About Dyadic International (NASDAQ:DYAI) StockDyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.Read More DYAI Stock News HeadlinesJuly 5, 2022 | finance.yahoo.comDyadic to Participate in Bio-Manufacturing Innovation Summit and NIIMBL National MeetingJune 15, 2022 | americanbankingnews.comDyadic International, Inc. (NASDAQ:DYAI) Sees Significant Drop in Short InterestJune 3, 2022 | morningstar.comDyadic to Present at 2022 Jefferies Healthcare Conference | MorningstarMay 28, 2022 | finance.yahoo.comThe five-year returns have been decent for Dyadic International (NASDAQ:DYAI) shareholders despite underlying losses increasingMay 20, 2022 | finance.yahoo.comDyadic to Present at H.C. Wainwright Global Investment ConferenceMay 13, 2022 | finance.yahoo.comDYAI: First Quarter 2022 Operational & Financial ResultsMay 13, 2022 | seekingalpha.comDyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q1 2022 Results - Earnings Call TranscriptMay 13, 2022 | finance.yahoo.comDyadic Reports First Quarter 2022 Financial Results and Highlights Recent Company DevelopmentsMay 11, 2022 | seekingalpha.comDyadic announces research, license and collaboration to make animal free ingredientsMay 11, 2022 | finance.yahoo.comDyadic Announces Research, License and Collaboration for the Manufacture of Animal Free IngredientsMay 9, 2022 | finance.yahoo.comDyadic Announces Successful Toxicology Data Published in “Toxicologic Pathology”April 28, 2022 | finance.yahoo.comDyadic to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022April 13, 2022 | seekingalpha.comDyadic licensee Epygen Biotech gets India govt funding to develop a COVID-19 shotApril 13, 2022 | finance.yahoo.comIndia Funds Affordable COVID-19 Vaccine Candidate Using Dyadic's PlatformApril 13, 2022 | finance.yahoo.comEpygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic’s Licensed C1 Protein Production PlatformApril 4, 2022 | finance.yahoo.comWe're Not Worried About Dyadic International's (NASDAQ:DYAI) Cash BurnMarch 30, 2022 | uk.finance.yahoo.comDyadic International, Inc. (DYAI)March 30, 2022 | finance.yahoo.comDYAI: 2021 ResultsMarch 28, 2022 | markets.businessinsider.comDyadic International earnings preview: what Wall Street is expectingMarch 28, 2022 | benzinga.comA Preview Of Dyadic International's EarningsMarch 19, 2022 | benzinga.comDyadic International, Sorrento Therapeutics Mutually Agreed To Terminate The Term SheetMarch 15, 2022 | tmcnet.comDyadic to Report 2021 Year-End Financial ResultsMarch 15, 2022 | benzinga.comDyadic to Report 2021 Year-End Financial Results on Tuesday, March 29, 2022February 7, 2022 | finance.yahoo.comDyadic International’s CEO Mark Emalfarb to Present at BIO CEO & Investor ConferenceFebruary 7, 2022 | finance.yahoo.comDyadic International’s CEO Mark Emalfarb to Present at BIO CEO & Investor ConferenceSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DYAI CUSIPN/A CIK1213809 Webwww.dyadic.com Phone(561) 743-8333Fax561-743-8343Employees7Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today7/05/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$6.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+97.4%Consensus RatingBuy Rating Score (0-4)3 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,070,000.00 Net Margins-473.45% Pretax Margin-473.45% Return on Equity-61.46% Return on Assets-54.44% Debt Debt-to-Equity RatioN/A Current Ratio8.89 Quick Ratio8.89 Sales & Book Value Annual Sales$2.40 million Price / Sales35.80 Cash FlowN/A Price / Cash FlowN/A Book Value$0.65 per share Price / Book4.68Miscellaneous Outstanding Shares28,260,000Free Float20,774,000Market Cap$85.91 million OptionableNot Optionable Beta0.27 Dyadic International Frequently Asked Questions Should I buy or sell Dyadic International stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dyadic International in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Dyadic International stock. View analyst ratings for Dyadic International or view top-rated stocks. What is Dyadic International's stock price forecast for 2022? 1 analysts have issued 1 year price targets for Dyadic International's shares. Their DYAI stock forecasts range from $6.00 to $6.00. On average, they predict Dyadic International's share price to reach $6.00 in the next year. This suggests a possible upside of 97.4% from the stock's current price. View analysts' price targets for Dyadic International or view top-rated stocks among Wall Street analysts. How has Dyadic International's stock price performed in 2022? Dyadic International's stock was trading at $4.52 on January 1st, 2022. Since then, DYAI shares have decreased by 32.7% and is now trading at $3.04. View the best growth stocks for 2022 here. When is Dyadic International's next earnings date? Dyadic International is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for Dyadic International. How were Dyadic International's earnings last quarter? Dyadic International, Inc. (NASDAQ:DYAI) announced its earnings results on Thursday, May, 12th. The biotechnology company reported ($0.09) EPS for the quarter, meeting analysts' consensus estimates of ($0.09). The biotechnology company earned $0.65 million during the quarter, compared to analyst estimates of $2.37 million. Dyadic International had a negative trailing twelve-month return on equity of 61.46% and a negative net margin of 473.45%. View Dyadic International's earnings history. Who are Dyadic International's key executives? Dyadic International's management team includes the following people: Mr. Mark A. Emalfarb, Founder, CEO, Pres & Director (Age 66, Pay $759.49k) (LinkedIn Profile)Ms. Ping Wang Rawson CPA, M.B.A., Chief Financial Officer (Age 46, Pay $309.98k) (LinkedIn Profile)Mr. Joseph P. Hazelton, Chief Bus. OfficerDr. Ronen Tchelet Ph.D., VP of Research & Bus. Devel. (Age 64, Pay $255.24k)Ms. Ana Gómez Rodriguez, Sec. of the Board Who are some of Dyadic International's key competitors? Some companies that are related to Dyadic International include Forma Therapeutics (FMTX), Humacyte (HUMA), MeiraGTx (MGTX), Caribou Biosciences (CRBU), Mesoblast (MESO), Tarsus Pharmaceuticals (TARS), bluebird bio (BLUE), Vickers Vantage Corp. I (VCKA), DBV Technologies (DBVT), Opthea (OPT), GreenLight Biosciences (GRNA), Eiger BioPharmaceuticals (EIGR), AlloVir (ALVR), Compass Therapeutics (CMPX) and Adaptimmune Therapeutics (ADAP). View all of DYAI's competitors. What other stocks do shareholders of Dyadic International own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dyadic International investors own include Silvercorp Metals (SVM), Endeavour Silver (EXK), Hecla Mining (HL), Pfizer (PFE), Advanced Micro Devices (AMD), Endeavour Silver (EDR), Mandalay Resources (MND), Ampio Pharmaceuticals (AMPE), Alibaba Group (BABA) and Chimerix (CMRX). What is Dyadic International's stock symbol? Dyadic International trades on the NASDAQ under the ticker symbol "DYAI." How do I buy shares of Dyadic International? Shares of DYAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Dyadic International's stock price today? One share of DYAI stock can currently be purchased for approximately $3.04. How much money does Dyadic International make? Dyadic International (NASDAQ:DYAI) has a market capitalization of $85.91 million and generates $2.40 million in revenue each year. The biotechnology company earns $-13,070,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. How many employees does Dyadic International have? Dyadic International employs 7 workers across the globe. How can I contact Dyadic International? Dyadic International's mailing address is 140 INTRACOASTAL POINTE DRIVE SUITE 404, JUPITER FL, 33477. The official website for Dyadic International is www.dyadic.com. The biotechnology company can be reached via phone at (561) 743-8333, via email at prawson@dyadic.com, or via fax at 561-743-8343. This page (NASDAQ:DYAI) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here